June 25, 2014

Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.


The presentation covered the following topics:

    --  A status report on the first FDA approved study of Hemopurifier therapy
        in the United States, including Aethlon's clinical progression strategy
        to advance infectious disease and oncology treatment indications.

    --  A review of clinical safety data and efficacy observations resulting
        from Hemopurifier administration to HIV and Hepatitis c (HCV) infected

    --  The results of government and non-government collaborative testing
        programs against category "A" bioterror and pandemic threats, including
        pandemic influenza, dengue, ebola, pox viruses, and other viral
        pathogens that remain untreatable with drug or vaccine therapies.

    --  The discovery that the Aethlon Hemopurifier captures tumor-secreted
        exosomes underlying a broad-spectrum of cancer indications and the
        resulting patent protection already issued to protect Aethlon's cancer
        treatment endeavors.

    --  A review of a National Cancer Institute (NCI) sponsored publication that
        references Aethlon Medical as the first organization with a therapeutic
        candidate to address tumor-secreted exosomes.

    --  A review of recent landmark discoveries that tumor-secreted exosomes
        suppress the immune system of cancer patients, seed the creation and
        spread of metastasis, promote angiogenesis, and transport PD-1, PDL-1,
        VEGF, CTLA-4, EGRF and other primary cancer therapeutic targets of the
        biopharmaceutical industry.

    --  The central role of the Aethlon Hemopurifier in the rapidly emerging
        immuno-oncology industry, which analysts expect to grow to $35 billion
        per year in the near future.
    --  The recent launch of Aethlon's Exosome Sciences diagnostic subsidiary,
        which is the first organization to demonstrate the ability to isolate
        exosomes that transport diagnostic biomarkers underlying alzheimer's
        disease (AD), chronic traumatic encephalopathy (CTE), and glioblastoma
        multiforme (GBM) that have crossed through blood brain barrier into the
        circulatory system. Thus, setting the stage for liquid biopsies that
        allow for the identification and monitoring of these disease conditions.

About Aethlon Medical

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT(TM) system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


James A. Joyce

Chairman and CEO

858.459.7800 x301

[email protected]

Jim Frakes

Chief Financial Officer

858.459.7800 x300

[email protected]


Photo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

Logo - http://photos.prnewswire.com/prnh/20130912/LA78266LOGO

SOURCE Aethlon Medical, Inc.